June 2019 Shareholder and Stakeholder Letter
Alitair to Attend 37th Annual J.P. Morgan Healthcare Conference
Dear Shareholders and Stakeholders,
As we approach the end of the 2nd Quarter, I wanted to provide an update on our business and our planned endeavors for 3Q19. Overall, our executive team is working diligently to make sure the promise of Alitair remains alive and that our firm remains very investable. Our target markets, our pipeline, our intellectual property, our clinical development and our regulatory strategy all remains very viable. And, the long-term opportunity to capture increasing value for shareholders and stakeholders is exciting.
Year End 2018 Shareholder Letter
ALITAIR will attend the 37th annual J.P. Morgan Healthcare Conference from January 7-10, 2019 in San Francisco, California. The J.P. Morgan Healthcare Conference is one of largest conferences in the life sciences industry.
3rd Quarter 2018 Shareholder Letter
Now that 2018 has ended, I would like to provide an update to our external shareholders and stakeholders. First, I would like to reaffirm that the potential of the Alitair pipeline remains strong and relevant in terms of meeting unmet medical needs. Our valuation has held firm. And, helping treat respiratory disease and providing solutions for the Opioid Crisis are central to our mission.
Alitair now on Facebook
Dear Valued Alitair Shareholder,
I want to provide you with a brief update on Alitair Pharmaceuticals.
Critical Need for More Capital
Alitair requires additional capital to fund its 24-month Clinical Development Plan and for General Corporate Purposes. I am limited to what I can say as Alitair is working through the final steps of a closing process to raise capital with two funding sources -- one a new investment fund that targets Alternate Investment from endowment funds from major non-profit health systems and the other a Healthcare Investment Bank. Together, these two entities will provide new capital to help grow our company.
Alitair Presents at National Investment Banking Association Meeting in New York City (Click for Video)
Alitair launches a Facebook page — focused on biopharma news and information relevant to the therapeutics areas of our medicines. This includes bronchiectasis, cough, and providing solutions for the abuse and misuse of prescription drugs. You can find the Alitair Facebook page at www.facebook.com/alitairpharma. Please “Like” and “Follow” our Alitair Facebook page.
Alitair Announces Issuance of Patent Covering its Prescription Drug Overdose Reduction Technology, ODR™
Alitair Pharmaceuticals CEO, James Hoyes, presents the corporate overview and strategic direction during the National Investment Banking Association (NIBA) Meeting in NYC. The meeting ran February 27-28, 2017.
Mr. Hoyes focused on the proprietary ion-exchange resin formulation technology that supports the highly innovative Overdose Reduction technology and forms the basis of its non-narcotic and narcotic prescription cough medicines portfolio. The Overdose Reduction technology, called ODR, may serve as a significant product in the fight against the Opioid Crisis. ODR serves to minimize the risk of overdose due to the abuse and/or misuse of prescription medicines especially opioids and benzodiazepines. Mr. Hoyes also reviewed the portfolio of Orphan Drugs focused on the rare pulmonary disease called bronchiectasis.
Alitair Pharmaceuticals, Inc. Selected to Present at Cavendish Global Health Impact Forum
Alitair Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on respiratory health, today announced the issuance of U.S. Patent No. 9,211,292, covering its prescription drug overdose reduction technology, ODR™ .
Alitair Pharmaceuticals, Inc., a clinical stage pharmaceutical company with multiple respiratory product candidates in development, announced today that it has been selected to present at the Cavendish Global Health Impact Forum co-hosted by the Cleveland Clinic in Cleveland, Ohio, October 25 - 28, 2015.